Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Files for IPO; Pricing Not Yet Determined

NEW YORK (GenomeWeb News) - NimbleGen has filed for an initial public offering with the Securities and Exchange Commission, the company said Friday.
The number and prices of shares have not yet been determined.
NimbleGen is a microarray developer that specializes in products and services for comparative genomic hybridization, chromatin immunoprecipitation arrays, comparative genome sequencing, and expression analysis.
J.P. Morgan will serve as bookrunner for the offering, Thomas Weisel Partners will be co-lead manager, and Leerink-Swan and Robert W. Baird are acting co-managers.
NimbleGen has signed several agreements to secure fundamental array IP over the last six months. Last October, the company licensed the rights to Affymetrix’s microarray patents, and in January it licensed rights to Oxford Gene Technology’s patents.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.